Advertisement

Topics

UB spinoff company For-Robin moves one step closer to human clinical trials

20:00 EDT 16 Oct 2017 | AAAS

(University at Buffalo) Scientists from For-Robin Inc., a University at Buffalo biotechnology spinoff, have published new scientific results showing that the company's cancer-fighting antibody can target, penetrate and kill human tumor cells effectively. The findings bring the company closer to human clinical trials.

Original Article: UB spinoff company For-Robin moves one step closer to human clinical trials

NEXT ARTICLE

More From BioPortfolio on "UB spinoff company For-Robin moves one step closer to human clinical trials"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...